Singapore markets open in 4 hours 59 minutes

Straits Times Index
3,300.04
-3.15(-0.10%)
S&P 500
5,187.69
+6.95(+0.13%)
Dow
38,883.80
+31.53(+0.08%)
Nasdaq
16,332.56
-16.69(-0.10%)
Bitcoin USD
63,040.75
-153.68(-0.24%)
CMC Crypto 200
1,309.09
-56.03(-4.10%)

LYEL Jul 2024 2.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.4500

0.0000

(0.00%)

As of 10:27AM EDT. Market open.

Simply Wall St.
Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
Lyell Immunopharma ( NASDAQ:LYEL ) First Quarter 2024 Results Key Financial Results Net loss: US$60.7m (loss narrowed...
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports
Simply Wall St.
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over...